Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for XBiotech Inc. (XBIT : NSDQ)

• Company Description    XBiotech Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing True Human(TM) monoclonal antibodies for treating diseases. XBiotech Inc. is based in AUSTIN, United States. Number of Employees: 85

• Price / Volume Information    Yesterday's Closing Price: $2.43 Daily Weekly Monthly 20 Day Moving Average: 25,513 shares Shares Outstanding: 30.49 (millions) Market Capitalization: $74.09 (millions) Beta: 0.88 52 Week High: $3.61 52 Week Low: $2.09 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -3.95% -8.64% 12 Week 3.40% -4.41% Year To Date 1.67% -4.60%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 5217 WINNEBAGO LANE - AUSTIN,TX 78744 USA ph: 512-386-2900 fax: 512-386-5505 swhitehurst@xbiotech.com http://www.xbiotech.com

• General Corporate Information    Officers Sushma Shivaswamy - Chief Executive Officer John Simard - Chairman Angela Hu - Principal Financial Officer and Principal Accounti Thomas Kuendig - Director Craig Rademaker - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 98400H102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/12/26 Share - Related Items Shares Outstanding: 30.49 Most Recent Split Date: (:1) Beta: 0.88 Market Capitalization: $74.09 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.55 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 50.00% vs. Previous Quarter: 79.55% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -26.10 12/31/25 - -27.80 09/30/25 - -16.73 ROA 03/31/26 - -25.06 12/31/25 - -26.67 09/30/25 - -15.93 Current Ratio 03/31/26 - 39.03 12/31/25 - 16.01 09/30/25 - 41.78 Quick Ratio 03/31/26 - 39.03 12/31/25 - 16.01 09/30/25 - 41.78 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 4.43 12/31/25 - 4.60 09/30/25 - 5.48 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©